A new study reports that cannabidiol (CBD) packaged in albumin nanoparticles can improve brain delivery and protect neurons in Alzheimer’s models. The approach addresses a central barrier for neurotherapeutics: getting enough drug into the brain in a bioactive form. By refining delivery rather than changing the active compound, the work positions nanoformulations as a way to unlock CBD’s neuroprotective and anti-inflammatory potential. The report ties improved delivery performance to neuronal protection outcomes. For drug developers exploring central nervous system targets, the study underscores that formulation and delivery engineering can be as decisive as target biology for therapeutic exposure in the brain.